GT Biopharma, a company that develops novel immuno-oncology biopharmaceutical drugs, is looking to be listed on the Nasdaq. The company is currently listed on the Over-the-Counter Markets under the ticker symbol "GTBP." It hopes to trade on the Nasdaq under the same ticker symbol.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.19 |
|---|---|
| 52-week range | $1.92 - $10.66 |
| 50-day moving average | $2.43 |
| 200-day moving average | $3.23 |
| Wall St. target price | $150.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-7.76 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.1356 from 2024-11-19
| 1 week (2024-11-13) | 2.47% |
|---|---|
| 1 month (2024-10-18) | 36.93% |
| 3 months (2024-08-20) | 46.52% |
| 6 months (2024-05-20) | -59.80% |
| 1 year (2023-11-20) | 1,251.55% |
|---|---|
| 2 years (2022-11-18) | -94.67% |
| 3 years (2021-11-19) | 149.7 |
| 5 years (2019-11-20) | 72.4199 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -60.59% |
| Return on equity TTM | -131.48% |
| Profit margin | 0% |
| Book value | $2.47 |
| Market Capitalization | $6.7 million |
TTM: trailing 12 months
We're not expecting Gt Biopharma Inc to pay a dividend over the next 12 months.
You may also wish to consider:
Gt Biopharma Inc's shares were split on a 1:30 basis on 4 February 2024 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Gt Biopharma Inc shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Gt Biopharma Inc shares which in turn could have impacted Gt Biopharma Inc's share price.
Over the last 12 months, Gt Biopharma Inc's shares have ranged in value from as little as $1.9201 up to $10.6599. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gt Biopharma Inc's is 0.57. This would suggest that Gt Biopharma Inc's shares are less volatile than average (for this exchange).
To put Gt Biopharma Inc's beta into context you can compare it against those of similar companies.
GT Biopharma, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.